Results 41 to 50 of about 62,041 (172)

Advancing Maternal Health with Long‐Acting Therapeutics: Priorities, Efficacy and Safety Considerations, and Emerging Technologies

Clinical Pharmacology &Therapeutics, EarlyView.
Maternal health remains a critical global concern, particularly in underserved populations and in low‐ and middle‐income countries where access to safe and effective therapeutics is limited. Despite the use of medications by most women during pregnancy, the exclusion of pregnant and lactating women from clinical trials has resulted in significant data ...
Rachel K. Scott, Sharon Nachman, Ethel D. Weld, Rachel Daley, Shakir Atoyebi, Robert Bies, Catriona Waitt, Adeniyi Olagunju   +7 more
wiley   +1 more source

Lower genetic variability of HIV-1 and antiretroviral drug resistance in pregnant women from the state of Pará, Brazil

BMC Infectious Diseases, 2017
Background The present study aimed to describe the genetic diversity of HIV-1, as well as the resistance profile of the viruses identified in HIV-1 infected pregnant women under antiretroviral therapy in the state of Pará, Northern Brazil.
Luiz Fernando Almeida Machado, Iran Barros Costa, Maria Nazaré Folha, Anderson Levy Bessa da Luz, Antonio Carlos Rosário Vallinoto, Ricardo Ishak, Marluisa Oliveira Guimarães Ishak   +6 more
doaj   +1 more source

Exploring the hydrophobic channel of NNIBP leads to the discovery of novel piperidine-substituted thiophene[3,2-d]pyrimidine derivatives as potent HIV-1 NNRTIs

Acta Pharmaceutica Sinica B, 2020
In this report, a series of novel piperidine-substituted thiophene[3,2-d]pyrimidine derivatives were designed to explore the hydrophobic channel of the non-nucleoside reverse transcriptase inhibitors binding pocket (NNIBP) by incorporating an aromatic ...
Dongwei Kang, Da Feng, Tiziana Ginex, Jinmi Zou, Fenju Wei, Tong Zhao, Boshi Huang, Yanying Sun, Samuel Desta, Erik De Clercq, Christophe Pannecouque, Peng Zhan, Xinyong Liu   +12 more
doaj   +1 more source

Prevalence of HIV-1 drug resistance among women screening for HIV prevention trials in KwaZulu-Natal, South Africa (MTN-009). [PDF]

PLoS ONE, 2013
A major concern with using antiretroviral (ARV)-based products for HIV prevention is the potential spread of drug resistance, particularly from individuals who are HIV-infected but unaware of their status.
Urvi M Parikh, Photini Kiepiela, Shayhana Ganesh, Kailazarid Gomez, Stephanie Horn, Krista Eskay, Cliff Kelly, Barbara Mensch, Pamina Gorbach, Lydia Soto-Torres, Gita Ramjee, John W Mellors, MTN-009 Protocol Team, IPTc Taskforce   +13 more
doaj   +1 more source

Advances in Double‐Stranded DNA Targeting Technologies

Exploration, EarlyView.
Double‐stranded DNA (dsDNA) plays a crucial role in genetic information storage and disease management, but its inherent stability limits access to internal bases. To overcome this challenge, various high‐specificity molecular targeting technologies have been developed to destabilize the DNA structure.
Zuhao Shen, Yiqun Liu, Yingjie Hao, Yifan Bo, Xiaochuan Dai, Shihui Wang, Tian Xia, Xin Su, Huiyu Liu   +8 more
wiley   +1 more source

Increased risk of Q151M and K65R mutations in patients failing stavudine-containing first-line antiretroviral therapy in Cambodia.

PLoS ONE, 2013
BackgroundMulti-nucleos(t)ide resistance (MNR) mutations including Q151M, K65R mutations, and insertion at codon 69 of HIV-1 reverse transcriptase coding region may confer resistance to all molecules of nucleos(t)ide reverse transcriptase inhibitors ...
Janin Nouhin, Yoann Madec, Nicole Ngo-Giang-Huong, Laurent Ferradini, Eric Nerrienet   +4 more
doaj   +1 more source

Structural Studies and Structure Activity Relationships for Novel Computationally Designed Non-nucleoside Inhibitors and Their Interactions With HIV-1 Reverse Transcriptase

Frontiers in Molecular Biosciences, 2022
Reverse transcriptase (RT) from the human immunodeficiency virus continues to be an attractive drug target for antiretroviral therapy. June 2022 will commemorate the 30th anniversary of the first Human Immunodeficiency Virus (HIV) RT crystal structure ...
Kathleen M. Frey, Nicole Bertoletti, Albert H. Chan, Joseph A. Ippolito, Mariela Bollini, Krasimir A. Spasov, William L. Jorgensen, Karen S. Anderson, Karen S. Anderson   +8 more
doaj   +1 more source

Time to treatment disruption in children with HIV-1 randomized to initial antiretroviral therapy with protease inhibitors versus non-nucleoside reverse transcriptase inhibitors.

PLoS ONE, 2020
BackgroundChoice of initial antiretroviral therapy regimen may help children with HIV maintain optimal, continuous therapy. We assessed treatment-naïve children for differences in time to treatment disruption across randomly-assigned protease inhibitor ...
Dwight E Yin, Christina Ludema, Stephen R Cole, Carol E Golin, William C Miller, Meredith G Warshaw, Ross E McKinney, PENPACT-1 (PENTA 9 / PACTG 390) Study Team   +7 more
doaj   +1 more source

HIV-1 Reverse Transcriptase Inhibition by Major Compounds in a Kenyan Multi-Herbal Composition (CareVid™): In Vitro and In Silico Contrast

Pharmaceuticals, 2021
CareVid is a multi-herbal product used in southwest Kenya as an immune booster and health tonic and has been anecdotally described as improving the condition of HIV-positive patients.
Winnie Rotich, Nicholas J. Sadgrove, Eduard Mas-Claret, Guillermo F. Padilla-González, Anastasia Guantai, Moses K. Langat   +5 more
doaj   +1 more source

Nature Inspired Delivery Vehicles for CRISPR‐Based Genome Editing

Small, EarlyView.
The review highlights nature‐inspired nanocarriers for CRISPR delivery, emphasizing viral vectors, extracellular vesicles, liposomes, and lipid nanoparticles. It discusses their roles in improving specificity, minimizing immunogenicity, and overcoming barriers in genome editing. Recent advancements, challenges, and therapeutic applications are explored,
Elizabeth Maria Clarissa, Mamata Karmacharya, Hyunmin Choi, Sumit Kumar, Yoon‐Kyoung Cho   +4 more
wiley   +1 more source